DRKS00025948
Recruiting
Phase 2
Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer - Pembro-SRT
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Recurrent prostate cancer
- Sponsor
- niversitätsklinikum Freiburg
- Enrollment
- 49
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male patients who are at least 18 years of age on the day of signing informed consent.
- •2\. Histologically confirmed diagnosis of an adenocarcinoma of the prostate and a BCR or PSA persistence after RP.
- •3\. Histology of the RP specimen needs to fulfill the following criteria: adenocarcinoma of the prostate, Gleason score 7\-10; pNX or pN0 or pN1 (max. 2 lymph nodes involved).
- •4\. Imaging within 50 days prior to study inclusion is mandatory (patient registration) \[68Ga] or \[18F] PSMA PET\-CT as standard imaging modality, alternatively CT abdomen and full\-body bone scan).
- •5\. PSA value between \=0\.2 and \=1\.0 ng/ml measured at least six weeks postoperatively.
- •6\. The patients agree not to undergo testicular sperm extraction for at least 90 days after the last administration of pembrolizumab. (Due to prior surgical removal of the prostate no contraception is necessary.)
- •7\. Written informed consent obtained according to international guidelines and local law.
- •8\. Patients further having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\.
- •9\. Patients with adequate organ function as defined in Table 2\.
Exclusion Criteria
- •1\. Prior\-therapy with an anti\-PD\-1, anti\-PD\-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co\-inhibitory T\-cell receptor (e.g., CTLA\-4, OX 40, CD137\).
- •2\. Prior systemic anti\-cancer therapy including investigational agents within 4 weeks prior to registration (like neo\-adjuvant androgen deprivation therapy (ADT), secondary hormone ablation or taxan\-based chemotherapy).
- •3\. Prior radiotherapy within 4 weeks before start of study medication. Patients must have recovered from all radiation\-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
- •4\. Distant metastases or suspicious lymph nodes outside the lower pelvis in imaging with PSMA PET\-CT (patients with PET positive bone lesions that are morphologically not clearly suspicious of metastases and would not change clinical practice can be included).
- •5\. Adverse histology of RP specimen (e.g. neuroendocrine or small cell)
- •6\. Any vaccination with live vaccine or live\-attenuated vaccine within 30 days prior to the first dose of study medication. Administration of killed vaccine is allowed.
- •7\. Currently or previously participating in a study of an investigational product within 4 weeks prior to the first dose of study medication.
- •8\. Diagnosis of immunodeficiency, chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication.
- •9\. History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
- •10\. Known active CNS metastases and/or carcinomatous meningitis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
Evaluation of radiotherapy in combination with pembrolizumab in patients with recurrent prostate cancer after radical prostatectomyRecurrent prostate cancer - Patients with biochemical recurrence (BCR) or persisting prostate-specifiv antigen (PSA) after radical prostatectomy (RP)Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]EUCTR2021-001291-42-DEniversitätsklinikum Freiburg49
Active, Not Recruiting
Phase 1
Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphomaCutaneous T cell lymphomaMedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-000433-30-GBniversity College London46
Recruiting
Phase 2
SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical ProstatectomyUrologic CancerBiochemical Recurrence of Malignant Neoplasm of ProstateNCT04931979Prof. Dr. med. Christian Gratzke49
Terminated
Phase 2
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BCMetastatic Breast CancerNCT03051672Dana-Farber Cancer Institute8
Active, Not Recruiting
Phase 2
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin LymphomaHodgkin LymphomaNCT03179917Memorial Sloan Kettering Cancer Center22